MARKET WIRESimply Wall St • 1d ago
AC Immune (Nasdaq:ACIU) - Stock AnalysisSimply Wall St report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
Why ACIU Stock dropped -7.21% Today — RQD Quant Desk Flash
$2.06 -7.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.03
AC Immune SA (ACIU) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $209.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ACIU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ACIU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, AC Immune SA (NASDAQ: ACIU) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.06 (-7.21% 1D, market cap $209.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ACIU ranks #368 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ACIU compare to NATR and SIGA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACIU carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $211.5M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $212.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ACIU?
▼
For AC Immune SA (ACIU), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #368 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.03 (-1.49%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACIU)Realized 20D OHLCV Swing Band: ±10.4%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY ACIU SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($5.9M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$2.40+2.9% Next Q
53
Q2 (-2Q)Grade C-$2.47-4% Next Q
50
Q3 (-1Q)Grade D$2.37-13.1% Next Q
48
CurrentGrade D$2.06-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ACIU Turnaround Squeeze
While ACIU currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.57) and Max Pain ($2.16) forces dealer call-delta covering toward $4.09.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACIU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACIU Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ACIU Stock dropped -7.21% Today — RQD Quant Desk Flash
AC Immune SA (ACIU) dropped -7.21% to $2.06, trading at 2% of its 52-week range ($2.03 – $3.9). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($2.03 – $3.9) with RSI-14 at 34 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.4% around $2.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $5.9M annual free cash flow.
Live ACIU Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 2d ago
AC Immune SA (ACIU) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 2d ago
NeuroSense Therapeutics Ltd. (NRSN) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 2d ago
CuriosityStream And Two Other Promising Penny Stocks To WatchSimply Wall St report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Largest Companies by Market Cap: U.S. StocksTradingKey report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 2d ago
Elicio Therapeutics, Inc. (ELTX) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACIU)
- ✓Walkthrough of ACIU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ACIU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.56%🛡️ HOLDING TREND SUPPORT
2026-11-04O $2.22H $2.22L $2.06C $2.06VOL 470.8K
RES: $2.98SUP: $2.02SMA50: $2.57SMA200: $2.71
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ACIU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ACIU today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ACIU. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACIU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACIU)
Health Care Rank #368 of 1015
⚔️ NATR vs ACIU Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ACIU vs. NATR, SIGA, ELDN, KROS)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, AC Immune SA (ACIU) ranks #368 by composite RQD confidence (45/100, grade D) and #564 by equity capitalization ($209.7M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with ACIU at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACIU
ACTIVE
AC Immune SA | D | 45/100 | — | — | — | -7.21% | $209.7M | Benchmark Subject |
| NATR Nature's Sunshine Products Inc. | C | 64/100 | 11.1x | 72.4% | 28.9% | -1.88% | $211.5M | /natr-vs-aciu → |
| SIGA SIGA Technologies Inc. | C+ | 68/100 | 9.8x | 68.6% | 42.7% | -2.96% | $212.0M | /siga-vs-aciu → |
| ELDN Eledon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | -5.41% | $212.9M | /eldn-vs-aciu → |
| KROS Keros Therapeutics Inc. | C | 64/100 | — | — | 85.0% | -2.54% | $213.3M | /kros-vs-aciu → |
2. ACIU Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTAC Immune SA (ACIU) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $209.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. ACIU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ACIU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, AC Immune SA (NASDAQ: ACIU) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.06 (-7.21% 1D, market cap $209.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ACIU ranks #368 in composite RQD confidence.
How does ACIU compare to NATR and SIGA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACIU carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $211.5M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $212.0M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ACIU?
For AC Immune SA (ACIU), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #368 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ACIU trading relative to its 50-day, 200-day, and 52-week technical levels?
ACIU last traded at $2.06 (-7.21% on volume of 470,837 shares), positioning the stock -19.84% below its 50-day simple moving average ($2.57) and -23.99% below its 200-day simple moving average ($2.71). Across its 52-week range of $2.03 to $3.90, ACIU sits at the 1.6% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.4% ($1.85 to $2.27).
ROARABLE RATING BRIEF • RQD 45/100 (D)
✓ SEC XBRL & RQD VERIFIED
ACIU — AC Immune SA: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
AC Immune SA (ACIU) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.06 (-7.21% 1D, market capitalization $209.7M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
AC Immune SA (ACIU) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile lists a market capitalization of $0.2B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.03 – $3.90 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations.0 per market data.
- Key Question #1: Can ACIU sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $3.90 52-week high?
- Key Question #3: How sensitive is ACIU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ACIU Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for AC Immune SA (ACIU) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Simply Wall St • 1d ago
AC Immune (Nasdaq:ACIU) - Stock Analysis Simply Wall St report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
AC Immune SA (ACIU) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Most Active Stocks Today: U.S. Market TradingKey report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
NeuroSense Therapeutics Ltd. (NRSN) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 2d ago
CuriosityStream And Two Other Promising Penny Stocks To Watch Simply Wall St report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Largest Companies by Market Cap: U.S. Stocks TradingKey report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 2d ago
Elicio Therapeutics, Inc. (ELTX) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering AC Immune SA (ACIU) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ACIU Bull vs. Bear Conversation Board — What's Your Call at $2.06?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACIU 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $2.93 (+32.0%)
📌 Pinned Debate The balance sheet is the strongest pillar, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 supporting stability.
Long ACIU at $2.22 targeting $2.93. The balance sheet is the strongest pillar, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 supporting stability.. Institutional whale score is 3/20 and the risk/reward vs. the $2.03 52-week low is skewed heavily in favor of bulls.
VolSurface_Trader 🐂 BULL
@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $2.22 is dangerous when funds are rotating into Health Care.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $1.75 (-21.2%)
Spot @ $2.22 ROIC and FCF yield are both 0% and institutional flow scores only 5 of 20, signaling weak cash generation and conviction.
Here is the bear case nobody on the bull side wants to address on ACIU: ROIC and FCF yield are both 0% and institutional flow scores only 5 of 20, signaling weak cash generation and conviction.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.